Simvastatin Hydroxy Acid Ammonium - Amplicore
Alternative Names: AM-3101Latest Information Update: 21 Nov 2022
At a glance
- Originator Amplicore
- Class Antihyperlipidaemics
- Mechanism of Action HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Meniscus disorders
Most Recent Events
- 21 Nov 2022 Chemical structure information added
- 29 Sep 2022 University of Cincinnati plans a phase I/II trial for Cartilage disorders in the US (NCT05560477)
- 26 Mar 2021 Amplicore and University of Cincinnati plans an early stage clinical trial to evaluate the safety and efficacy of AM 3101 for Meniscus disorders (Adjuvant therapy)